Skip to main content

Drug Interactions between carvedilol and Trelegy Ellipta

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

carvedilol vilanterol

Applies to: carvedilol and Trelegy Ellipta (fluticasone / umeclidinium / vilanterol)

Using carvedilol together with vilanterol may reduce the benefits of both medications, since they have opposing effects in the body. In addition, carvedilol can sometimes cause narrowing of the airways, which may worsen your breathing problems or trigger severe asthmatic attacks. Carvedilol is normally not recommended if you have asthma, a history of asthma, or severe chronic obstructive pulmonary disease (COPD). Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact or are less likely to interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Minor

fluticasone vilanterol

Applies to: Trelegy Ellipta (fluticasone / umeclidinium / vilanterol) and Trelegy Ellipta (fluticasone / umeclidinium / vilanterol)

Information for this minor interaction is available on the professional version.

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.